Primary CNS lymphoma: Clinical presentation, pathological classification, molecular pathogenesis and treatment

Journal of the Neurological Sciences

Volumn 181, Issue 1-2, 2000, Pages 1-12

  Schlegel, Uwe ^a   Schmidt Wolf, Ingo G H ^a   Deckert, Martina ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Chemotherapy; Clinical presentation; Immunocompetence; Long term neurotoxicity; Molecular pathogenesis; Pathological classification; Primary CNS lymphoma; Radiotherapy; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; PROCARBAZINE; THIOTEPA; VINCA ALKALOID; VINCRISTINE; VINDESINE;

BRAIN LYMPHOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; NEUROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

CENTRAL NERVOUS SYSTEM NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY; HIV INFECTIONS; HUMANS; LYMPHOMA, B-CELL; PROGNOSIS; RADIOTHERAPY; SURVIVAL RATE;

EID: 0034548676     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(00)00385-3     Document Type: Review

References (99)

1. Classification, pathogenesis and molecular pathology of primary CNS lymphomas
2. Further evidence that 'malignant angioendotheliomatosis' is an angiotropic large-cell lymphoma
3. Angiotropic intravascular large-cell lymphoma with massive cerebral extension
4. AIDS-associated non-Hodgkin lymphoma
5. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome
6. Increasing incidence of primary brain lymphoma in the US
7. Tumours of the central nervous system
8. AIDS-related primary brain lymphomas: Histopathological and immunohistochemical study of 51 cases
9. AIDS-related central nervous system lymphomas
10. Primary central nervous system lymphomas in patients with AIDS
11. Epidemiology of primary CNS lymphoma
12. The impact of primary central nervous system lymphoma in AIDS patients: A population-based autopsy study from Oslo
13. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?
14. Primary central nervous system lymphoma: From clinical presentation to diagnosis
15. Primary lymphoma of the central nervous system. Clinicopathological study of experience at Stanford
16. Primary malignant lymphomas of the central nervous system in man
17. High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series
18. Primary cerebral malignant non-Hodgkin's lymphoma: A retrospective clinical study
19. Primary central nervous system lymphoma
20. Primary CNS lymphoma: Findings outside the brain
21. Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): How much staging is enough?
22. Primary central nervous system lymphoma
23. Primary intracerebral malignant lymphoma: Report of 248 cases
24. Radiographic findings in 32 cases of primary CNS lymphoma
25. Central nervous system lymphoma: Histologic types and CT appearance
26. The variable MR appearance of primary lymphoma of the central nervous system: Comparison with histopathologic features
27. CT and MR imaging in primary cerebral non-Hodgkin's lymphoma
28. Primary central nervous system lymphoma versus toxoplasmosis in AIDS
29. The therapy of primary brain lymphoma
30. Leptomeningeal tumor in primary central nervous system lymphoma: Recognition, significance, and implications
31. Primary leptomeningeal lymphoma: Report of nine cases, diagnosis with immunocytochemical analysis, and review of the literature
32. Combined systemic and intraventricular chemotherapy for primary CNS lymphoma: A pilot study
33. Apoptosis and apoptosis-related gene products in primary non-Hodgkin's lymphoma of the central nervous system
34. T-cell lymphoma in the CNS: Clinical and pathologic features
35. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
36. Pathogenesis and classification of primary central nervous system lymphoma: An update
37. Comparison of integrin adhesion molecules expressed by primary brain lymphomas and nodal lymphomas
38. Primary central nervous system lymphomas are derived from germinal center B cells and show a preferential usage of the V4-34 gene segment
39. VH gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity
40. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is compatible with histogenetic derivation from germinal center-related B cells
41. BCL-6 protein is expressed in germinal center B cells
42. BCL-6 mutations in normal germinalcenter B cells: Evidence for somatic hypermutation acting outside Ig loci
43. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes
44. Autoanti-red cell antibodies synthesized by patients with infectious mononucleosis utilize the VH4-21 gene segment
45. VH4-21, a human VH gene segment overrepresented in the autoimmune repertoire
46. Utilization of the VH4-21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus
47. Differential usage of an autoantibody-associated VH gene, VH4-21, by human B-cell tumors
48. Do superantigens play a role in lymphoproliferation?
49. Structural basis of the gp120 superantigen-binding site on human immunoglobulins
50. Human antibody responses to bacterial antigens: Studies of a model conventional antigen and a proposed model B cell superantigen
51. AIDS primary central nervous system lymphoma: Molecular analysis of the expressed VH genes and possible implications for lymphoma genesis
52. Primary central nervous system malignant non-Hodgkin's lymphomas from HIV-infected and non-infected patients: Expression of cellular surface proteins and Epstein-Barr viral markers
53. Epstein Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system
54. Diagnosis of AIDS-related focal brain lesions: A decision-making analysis based on clinical and neuroradiological characteristics combined with polymerase chain reaction assays in cerebrospinal fluid
55. Epstein-Barr virus in monitoring the response to therapy of AIDS-related primary central nervous system lymphoma
56. Human herpesvirus-6 and Epstein-Barr virus genome in primary cerebral lymphomas
57. Human herpesvirus 8 DNA in CNS lymphomas from patients with and without AIDS
58. HHV-8/KSHV is not associated with AIDS-related primary central nervous system lymphoma
59. HHV-8 and AIDS-related CNS lymphoma
60. The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas
61. Application of interphase fluorescent hybridization for the detection of the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas
62. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation
63. Involvement of the bcl-2 gene in human follicular lymphoma
64. DNS fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: Berrant CH gene rearrangements is follicle center-cell lymphoma
65. Involvement of BCL-6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma
66. The propensity to apoptosis of centrocytes and centroblasts correlates with elevated levels of intracellular myc protein
67. Primary central nervous system lymphomas. Immunophenotypic, virologic, and cytogenetic findings of three patients without immune defects
68. Frequent inactivation of CDKN2S and rare mutation of TP53 in PCNSL
69. Chromosomal imbalances in primary lymphomas of the central nervous system
70. Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type
71. Glucocorticoid treatment of primary CNS lymphoma
72. Sentinel lesions of primary CNS lymphoma
73. Glucocorticoid-induced long-term remission in primary cerebral lymphoma: Case report and review of the literature
74. Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315
75. Primary lymphoma of the brain: Results of management of a modern cohort with radiation therapy
76. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL)
77. Management of primary cerebral lymphoma with initial chemotherapy: Preliminary results and comparison with patients treated with radiotherapy alone
78. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas
79. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy
80. Chemotherapy is effective as early treatment for primary central nervous system lymphoma
81. The C5R protocol: A regimen of high-dose chemotherapy and radiotherapy in primary central nervous system lymphoma of patients with no known cause of immunosuppression
82. Combined modality therapy for primary central nervous system lymphoma
83. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome
84. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma
85. Pre-irradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of Radiation Therapy Oncology Group Protocol 88-06
86. Long-term survival in primary CNS lymphoma
87. Primary CNS lymphoma: Treatment with combined chemotherapy and radiotherapy
88. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients
89. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients
90. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma
91. Non-AIDS primary CNS lymphoma: First example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy
92. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary?
93. Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone
94. Additional experience with empiric radiotherapy for presumed human immunodeficiency virus-associated primary central nervous system lymphoma
95. Primary central nervous system lymphoma: A role for adjuvant chemotherapy
96. Involved field radiotherapy and intra-Ommaya methotrexate/ara-C in patients with AIDS-related lymphomatous meningitis
97. Long survival in patients with AIDS-related primary CNS lymphoma
98. Combined modality therapy in the treatment of primary central nervous system lymphoma in AIDS
99. Neurologic sequelae of treatment of primary CNS lymphomas